RxDoctor Payments Data

Blanca Fernandez, MD

Family Practice · Ponce, PRNPI 1083893515

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Johnson & Johnson at 30.8% of the total. Reporting peaked in 2019 at $1,145 and has fallen 89.9% since, to $116 in 2025.

$1,586in general payments, 2019–2025

Across 32 payments — averaging $49.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$489
  • GSK$293
  • AstraZeneca$222
  • Bayer$195
  • Boston Scientific$91
  • Lilly USA, LLC$91
  • plus $206 from 5 others

What the payments were for

  • Food & beverage$1,586100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few family practice providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$4,853
Medicare patients
12
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SynthroidLevothyroxine Sodium110$10,997
JardianceEmpagliflozin12$9,700
LantusInsulin Glargine,hum.Rec.Anlog33$4,984
Losartan Potassium182$2,567
Atorvastatin Calcium138$1,887
Glipizide32$1,006
Alendronate Sodium56$944
Levothyroxine Sodium46$914
Metoprolol Succinate46$854
Metformin Hcl95$795
Rosuvastatin Calcium42$743
Gabapentin43$678
Carvedilol40$636
Montelukast Sodium22$632
Tizanidine Hcl13$519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$17$10,997110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family practice providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other family practice in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →